Lakefront Biotherapeutics NV (AMS:LKFT)

Market Cap	1.71B +0.5%
Revenue (ttm)	1.04B +262.2%
Net Income	488.78M
EPS	7.42
Shares Out	65.90M
PE Ratio	3.51
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,904
Open	25.72
Previous Close	25.98
Day's Range	25.54 - 26.10
52-Week Range	22.62 - 32.74
Beta	0.12
Analysts	Hold
Price Target	30.28 (+16.46%)
Earnings Date	Aug 10, 2026

About AMS:LKFT

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relaps...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 558
• Stock Exchange: Euronext Amsterdam
• Ticker Symbol: LKFT

Financial Performance

In 2025, AMS:LKFT's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.

Analyst Summary

According to 9 analysts, the average rating for LKFT stock is "Hold." The 12-month stock price target is €30.28, which is an increase of 16.46% from the latest price.

Price Target

€30.28

(16.46% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 17, 2026

Data Sources Report a data error